申请人:Eldar-Finkelman Hagit
公开号:US20060069066A1
公开(公告)日:2006-03-30
Novel compounds designed to allow interactions with binding sites of GSK-3 and hence are capable of inhibiting GSK-3 activity, via inhibition of substrate binding are disclosed. Further disclosed are pharmaceutical compositions including same and methods of using same in the treatment of GSK-3 mediated conditions.
本发明揭示了一种新型化合物,设计用于与GSK-3的结合位点相互作用,从而能够通过抑制底物结合来抑制GSK-3活性。此外,还揭示了包括该化合物的制药组合物以及使用该组合物治疗GSK-3介导疾病的方法。